Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.53 Analyst target: $3.29 Upside: 114.77%
enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The company is headquartered in Saint-Laurent, Canada.
See the full interactive analysis & chart →Informational only — not investment advice.